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Regulation of E2F1 activity by acetylation
1996) and the oncoprotein MDM2 (Martin et al., 1995).Marian A.Martı´nez-Balba´s, Uta-Maria Bauer,
Negative regulators include the tumour supressor proteinSøren J.Nielsen, Alexander Brehm and
p53 (O’Connor et al., 1995) and the most importantTony Kouzarides1
regulator, the retinoblastoma protein RB (Flemington et al.,
Wellcome/CRC Institute and Department of Pathology, University of 1993; Hagemeier et al., 1993; Brehm et al., 1998; Luo
Cambridge, Tennis Court Road, Cambridge CB2 1QR, UK et al., 1998; Magnaghi-Jaulin et al., 1998). The RB–E2F
1Corresponding author complexes, which predominate in quiescent cells (Bagchi
e-mail: tk106@mole.bio.cam.ac.uk et al., 1991; Cao et al., 1992), act as repressors of
transcription. The E2F-bound RB represses transcriptionM.A.Martı´nez-Balba´s and U.-M.Bauer contributed equally to this work
actively by contact with promoter-bound proteins
(Weintraub et al., 1995; Zhang et al., 1999) and byDuring the G1 phase of the cell cycle, an E2F–RB
recruiting a histone deacetylase complex (Brehm et al.,complex represses transcription, via the recruitment
1998; Luo et al., 1998; Magnaghi-Jaulin et al., 1998).of histone deacetylase activity. Phosphorylation of RB
at the G1/S boundary generates a pool of ‘free’ E2F, During G1 phase, RB is phosphorylated, which blocks the
which then stimulates transcription of S-phase genes. binding of E2F–RB and releases transcriptionally active
Given that E2F1 activity is stimulated by p300/CBP E2F at the G1/S transition (reviewed by Mittnacht, 1998).
acetylase and repressed by an RB-associated Other levels of control that inﬂuence E2F activity include
deacetylase, we asked if E2F1 was subject to modiﬁca- its own phosphorylation (Dynlacht et al., 1994, 1997; Xu
tion by acetylation. We show that the p300/CBP- et al., 1994; Krek et al., 1995; Vandel and Kouzarides,
associated factor P/CAF, and to a lesser extent p300/ 1999), protein stabilization (Hateboer et al., 1996;
CBP itself, can acetylate E2F1 in vitro and that Hofmann et al., 1996; Campero and Flemington, 1997;
intracellular E2F1 is acetylated. The acetylation sites Martelli and Livingston, 1999) and regulation of its
lie adjacent to the E2F1 DNA-binding domain and intracellular location (de la Luna et al., 1996; Allen et al.,
involve lysine residues highly conserved in E2F1, 2 1997; Lindeman et al., 1997).
and 3. Acetylation by P/CAF has three functional There are ﬁve E2F family members that have highly
consequences on E2F1 activity: increased DNA-binding conserved DNA-binding and activation domains (Helin
ability, activation potential and protein half-life. These et al., 1992; Kaelin et al., 1992; reviewed by Dyson,
results suggest that acetylation stimulates the functions 1998; Helin, 1998) whereas a sixth protein, EMA, is only
of the non-RB bound ‘free’ form of E2F1. Consistent conserved in the DNA-binding domain. Three of these,
with this, we ﬁnd that the RB-associated histone E2F1, 2 and 3, have the ability to induce S phase (Johnson
deacetylase can deacetylate E2F1. These results identify et al., 1993; DeGregori et al., 1995; Lukas et al., 1996).
acetylation as a novel regulatory modiﬁcation that However, all E2F members are able to bind to a similar
stimulates E2F1’s activation functions. consensus sequence when heterodimerized with a member
Keywords: acetylation/E2F1/histone deacetylase/p300/ of the DP family (Girling et al., 1993; Wu et al., 1995).
P/CAF/retinoblastoma protein The activity of E2F is increased by the CBP co-activator
protein. Although the precise mechanism by which p300/
CBP stimulates transcription remains unclear, the discov-
ery that p300/CBP and an associated factor P/CAF have
Introduction histone acetylase activities suggests that these cofactors
may regulate transcription through acetylation (BannisterThe E2F family of transcription factors plays a critical
and Kouzarides, 1996; Ogryzko et al., 1996; Yang et al.,role in organizing early cell cycle progression by coordinat-
1996). Modiﬁcation of histones by addition of acetyling early cell cycle events with the transcription of genes
groups occurs to a certain degree when the histones arerequired for entry into S phase (Nevins, 1992; La Thangue,
associated with transcriptionally active DNA (Hebbes1994; Ohtani et al., 1995). Aberrant expression of E2F in
et al., 1988; Grunstein, 1997). Although the major targetshuman cells leads to tumour formation (Hunter and Pines,
of CBP/p300 and P/CAF are histones, these acetylases1994; Hall and Peters, 1996; Yamasaki et al., 1996),
also modify certain transcription factors such as TFIIEβ,underscoring the importance of E2F in growth control.
TFIIF, EKLF, p53, HMGI(Y) and GATA-1 (Gu andE2F activity is regulated principally by association with
Roeder, 1997; Imhof et al., 1997; Boyes et al., 1998;different regulators. E2F has an activation domain located
Munshi et al., 1998; Zhang and Bieker, 1998).near its C-terminus that harbours the binding of several
Given that E2F1 activity is regulated positively by theproteins that regulate its activity. Positively acting proteins
p300/CBP acetylase and negatively by an RB-boundinclude TATA box-binding protein (TBP; Hagemeier et al.,
deacetylase, we have examined whether E2F1 is regulated1993; Pearson and Greenblatt, 1997), the coactivator p300/
CBP (Trouche and Kouzarides, 1996; Trouche et al., by acetylation. Here we show that the acetylase P/CAF
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and to a lesser extent CBP and p300 can acetylate E2F1
in vitro and that E2F1 is acetylated in vivo. We show that
acetylation of E2F1 increases its DNA-binding ability, its
transcriptional activation capacity and its protein half-life.
The acetylation status of E2F1 is affected by the histone
deacetylase associated with the RB–E2F1 complex. These
data point to acetylation as a novel mechanism for the
regulation of E2F1 activity.
Results
E2F1 is acetylated
The CBP acetylase can bind E2F1 and stimulate its ability
to activate transcription (Trouche and Kouzarides, 1996;
Trouche et al., 1996). We set out to establish if acetylation
of E2F itself was part of the mechanism by which CBP
functioned. We ﬁrst tested if CBP or the closely related
enzyme p300 could acetylate recombinant GST–E2F1 in
vitro. Also included in this experiment was P/CAF (and
the close homologue GCN5) since this enzyme is found
associated with p300/CBP (Yang et al., 1996). The results
in Figure 1A show that recombinantly expressed P/CAF
acetylated E2F1 very potently. Longer exposure of the gel
shows that E2F1 was also acetylated less efﬁciently by
GCN5 and by the CBP and p300 HAT domains. The
speciﬁcity of the acetylation is demonstrated in Figure 1B,
where P/CAF is shown to acetylate GST–E2F1, but not
GST or bovine serum albumin (BSA). We estimate that
the proportion of recombinant E2F1 acetylated by P/CAF
in our assays is ~25%.
Fig. 1. Acetylation of E2F1 by P/CAF, GCN5, CBP and p300To verify that E2F1 is acetylated in vivo, we used an
acetylases. (A) In vitro acetylation of E2F1. Puriﬁed GST–E2F1
antibody raised against acetylated histone H4 that has the (amino acids 89–437) was incubated with [14C]acetyl-CoA and
ability to recognize acetylated proteins. Such antibodies recombinant GST–P/CAF (amino acids 352–832, lanes 1 and 5), His-
GCN5 (amino acids 1–427, lanes 2 and 6), GST–CBP (amino acidshave been used to establish whether the transcription
1098–1877, lanes 3 and 7) and His-p300 (amino acids 1071–1715,factors GATA1 and EKLF are acetylated in vivo. The
lanes 4 and 8). Reaction products were separated by SDS–PAGE and
endogenous E2F1 protein was therefore precipitated with gels were autoradiographed. Lanes 5–8 are a longer exposure (8 days)
an anti-E2F1-speciﬁc antibody or with the unrelated of lanes 1–4 (6 h) to visualize acetylation of E2F1 by GCN5, CBP
haemagglutinin (HA)-tagged antibody. The anti-acetylated and p300. (B) Control acetylation reactions with GST–E2F1, GST and
BSA were performed as described in (A) and show that E2F1 (lane 2)lysine antibody was then used in a Western blot analysis.
in the presence of [14C]acetyl-CoA, but in the absence of P/CAFFigure 1C shows that the speciﬁcally immunoprecipitated (lane 1) is not acetylated, and GST (lane 3) or BSA (lane 4), are notE2F1 protein is recognized by the anti-acetylated lysine targets for P/CAF. (C) In vivo acetylation of E2F1. Extracts from
antibody. Collectively, these results show that E2F1 is U2OS cells were prepared and E2F1 was immunoprecipitated using an
anti-E2F1 (C20) antibody or an anti-HA antibody as a control.acetylated in vivo and that P/CAF can acetylate E2F1
Immunoprecipitates were analysed by SDS–PAGE and Western blotefﬁciently in vitro.
analysis using an antibody raised against acetylated histone H4.
E2F1 can associate with P/CAF
We wanted to establish whether the P/CAF enzyme can interaction with E2F1 (lane 4). Further dissection points
to the ADA2 domain as the major determinant for theassociate with E2F1. Western blot analysis indicates that
intracellular levels of P/CAF are very low, or that P/CAF association (Figure 2C, lanes 5–9), although low afﬁnity
was exhibited by the HAT domain (lane 6). These resultsantibodies have low afﬁnity for the substrate (data not
shown). For these reasons, we transfected Flag-P/CAF suggest that P/CAF may bind to E2F1 independently of
p300/CBP, since the interaction site for p300/CBP liesinto cells and asked if it can be co-immunoprecipitated
with endogenous E2F1. Figure 2A shows that precipitation in the N-terminus of P/CAF (Yang et al., 1996; Reid
et al., 1998).of Flag-P/CAF results in co-precipitation of E2F1, which
was recognized in an anti-E2F1 Western blot. Figure 2B
shows that the reverse is also true, namely that precipitation Identifying acetylation sites in E2F1
We wanted to establish how acetylation regulates E2F1of E2F1 co-precipitates Flag-P/CAF.
Having established that the two proteins can interact activity. We argued that identiﬁcation of the lysines
modiﬁed by P/CAF may give clues to the functionin vivo, we set out to dissect the sites of interaction
between E2F1 and P/CAF. Figure 2C shows that in vitro regulated by acetylation. Deletion analysis indicated that
acetylation sites resided within a region of E2F1 (89–287)translated E2F1 can associate with GST–P/CAF (lane 3).
The C-terminus of P/CAF (352–832), which contains the that harbours the DNA-binding domain (Figure 3A and
B). This region contains several lysines, some of whichHAT, ADA2 and Bromo domains, is sufﬁcient for the
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Fig. 2. E2F1 interacts with P/CAF. (A) U2OS cells were transfected with 8 μg of pCX-P/CAF (Flag-tagged), and afterwards whole-cell extracts were
prepared and incubated with anti-Flag antibody and, as controls, either with anti-HA antibody or without any antibody. By incubation with
protein A–Sepharose, immunoprecipitates were collected. The precipitates were then analysed by SDS–PAGE and Western blotting with the anti-
E2F1 (C20) antibody for the presence of co-immunoprecipitated E2F1. (B) U2OS cells were transfected and extracted, as described in (A). In this
experiment, immunoprecipitation of E2F1 was performed with an anti-E2F1 antibody (C20). The control reactions were the same as in (A). An anti-
Flag Western blot was used for detection of co-immunoprecipitated P/CAF. (C) Schematic representation of P/CAF fragments used to identify the
E2F interaction region in P/CAF. E2F1 binding to different P/CAF fragments is indicated in the scheme. (D) The P/CAF fragments were expressed
as GST fusion proteins, puriﬁed and used in GST pull-down assays with in vitro translated, 35S-labelled E2F1 protein. Equivalent P/CAF protein
amounts of the different mutants were used. Interaction between E2F1 and P/CAF was analysed by SDS–PAGE of the pull-down reactions and
autoradiography (lanes 3–9). The input (lane 1) contains 20% of the E2F1 IVT. GST protein (lane 2) was used as a control.
are implicated in DNA binding, according to the recent E2F1 and E2F1-R mutant were used (data not shown).
These results indicate that P/CAF cannot acetylatecrystal structure of the E2F4–DP1–DNA complex (Zheng
et al., 1999). We mutated three clusters of lysines to E2F-R in vivo.
arginine. Two sets of lysines are within the DNA-binding
domain (KK 161,164 and KKK 182,183,185). All lysines Acetylation of E2F1 augments DNA binding
Having identiﬁed an E2F1 mutant that cannot be acetylated(except Lys161) are conserved in all six E2F family
members, and one of these, Lys182, makes direct contact by P/CAF, we set out to use this mutant to dissect the
functional consequence of E2F1 acetylation. Given thatwith DNA. Another set of mutated lysines falls directly
N-terminal and adjacent to the DNA-binding domain the acetylated residues are adjacent to the E2F1 DNA-
binding domain, we ﬁrst tested whether acetylation affec-(KKK 117,120,125), and they are only conserved in E2F1,
2 and 3. The three mutant E2F1 proteins and wild- ted the ability of E2F1 to recognize DNA.
In these experiments, we used recombinant E2F1 con-type E2F1 were expressed recombinantly, and equivalent
concentrations of each protein were tested for acetylation sisting of only the DNA-binding domain (residues 92–
195). This domain contains lysines 117, 120 and 125 andby P/CAF. Figure 3C shows that mutating the two lysine
clusters present within the DNA-binding domain can be acetylated by P/CAF (data not shown). Figure 4A
shows that this E2F1 domain can weakly bind an E2F(K161,164R and K182,183,185R) had no effect on
acetylation. In contrast, mutating the lysines that lie outside site DNA element (lanes 5–7), but when acetylated by
P/CAF this domain recognizes DNA 6-fold more efﬁci-the DNA-binding structure (K117,120,125R) generates
an E2F1 mutant that can no longer be acetylated by ently at the highest concentration (lanes 2–4).
In the cell, E2F1 binds to DNA as a dimer with theP/CAF. This mutant is referred to from here on as the
E2F1-R mutant. DP1 protein. We next tested whether the E2F1–DP1
heterodimer binds DNA more efﬁciently following theWe next asked if the E2F1-R mutant was defective for
acetylation by P/CAF in vivo. P/CAF was therefore acetylation of E2F1. Figure 4B shows that acetylation of
recombinant E2F1 by P/CAF increases DNA bindingtransfected into cells along with either wild-type E2F1 or
with the E2F1-R mutant. The anti-acetylated lysine anti- when dimerized with DP1 (lanes 7 and 8) compared with
a control reaction in which E2F1 was incubated with abody was then used to precipitate acetylated E2F1, which
was detected by Western blot analysis using an anti-E2F1 P/CAF mutant (ΔHAT) that has no HAT activity (lanes 5
and 6). To establish more deﬁnitely whether acetylationantibody. Figure 3D shows that the anti-acetylated lysine
antibody can precipitate wild-type E2F1 but not the E2F-R of E2F1 was causing the increase in DNA-binding poten-
tial, we used the E2F1-R mutant, which cannot bemutant. An E2F1 Western blot of the transfected cells
was used to make sure that equivalent protein levels of acetylated by P/CAF (Figure 3C). As seen in Figure 4C,
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Fig. 3. The E2F1 acetylation sites are located directly adjacent to the DNA-binding domain. (A) Identiﬁcation and evolutionary conservation of the
acetylation sites in E2F1. Schematic representation of E2F1, its functional domains, the three lysine clusters that were mutated to arginines, and
polypeptide sequence alignment of E2F1 (amino acids 114–185) with E2F2, E2F3, E2F4, E2F5 and EMA. The arrows indicate the mutated lysine
residues, the conservation of which is highlighted by boxes. The corresponding secondary structure of the E2F4 DNA-binding domain (Zheng et al.,
1999) with its four α-helices and two β-sheets is shown underneath the sequence alignment. The acetylated lysines are indicated by asterisks.
(B) The E2F1 fragments indicated (lanes 1–4) were expressed as GST fusion proteins, puriﬁed and 2 μg of each were assayed for acetylation by
GST–P/CAF as described in Figure 1A. (C) Wild-type (lane 1) and mutated E2F1 proteins (lanes 2–4), which were mutated at the indicated lysines
to arginines, were expressed, puriﬁed and 2 μg of each were assayed for acetylation by P/CAF. (D) To test in vivo acetylation of the E2F1-R mutant
[E2F1-K(117,120,125)R, (C) lane 4], P/CAF (8 μg of pCX-P/CAF) was co-transfected with either E2F1 (3 μg of pcDNA3-E2F1) or E2F1-R (6 μg
of pcDNA3-E2F1-R) into 293T cells. Acetylation of E2F1 and the mutant was investigated by immunoprecipitation of equivalent amounts of E2F1
and E2F1-R protein with an anti-acetylated lysine antibody covalently coupled to protein A–Sepharose and subsequent E2F1 Western blot analysis
(with KH95 antibody) of the precipitates.
the E2F1-R mutant is still able to bind DNA perfectly together, these results suggest that acetylation increases
the activation potential of E2F1.well in combination with DP1 (lanes 1–3). The DNA-
binding ability of the DP1–E2F1-R complex is not
increased, however, when E2F1-R is incubated with an P/CAF acetylation stabilizes E2F1 protein
During our analysis of E2F acetylation, a novel propertyactive P/CAF enzyme. This result demonstrates that the
presence of acetylation sites within E2F1 is essential for of P/CAF was uncovered, namely its ability to increase
the levels of E2F1 protein in the cell. Cycling cells possessthe stimulatory effect of P/CAF on E2F1 DNA binding.
low levels of E2F1 protein. Figure 6A shows that very
little endogenous E2F1 is detected when whole cells areAcetylation by P/CAF stimulates E2F1
transactivation potential lysed and Western blotted with an anti-E2F1 antibody
(lane 1). However, transfection of P/CAF into cells resultsSince acetylation increases DNA binding by E2F1, we
asked if acetylation by P/CAF regulates the transactivation in a signiﬁcant increase in the levels of E2F1 (lane 2).
P/CAF HAT activity seems essential for this increase inpotential of E2F1. Figure 5A shows that overexpression
of P/CAF stimulates the ability of an E2F1–DP1 hetero- E2F1 since a HAT mutant of P/CAF (which is expressed
at levels equal to the wild-type) does not show this effectdimer to activate transcription of a promoter bearing E2F1
elements. P/CAF had no effect on a promoter containing (lane 3). Other acetylases, GCN5 and p300, do not increase
the levels of E2F1 signiﬁcantly in the cell (lanes 4 andmutated E2F-binding sites (data not shown). The stimula-
tion by P/CAF is dependent on P/CAF HAT activity since 5). Similar observations regarding E2F1 stability have
been reported for the RB protein (Martelli and Livingston,a P/CAF mutant (ΔHAT) that lacks acetylation capacity
cannot augment E2F1–DP1 activity. The ability of P/CAF 1999). Under our conditions, transfection of RB leads to
an increase in E2F1 protein levels, comparable with thoseto act as a co-activator depended on its ability to acetylate
E2F1. This is evident when we use the E2F1-R mutant, seen with P/CAF (Figure 6A, lane 6).
If the increase in stability of E2F1 occurs as a resultwhich cannot be acetylated by P/CAF, but which can still
bind DNA efﬁciently. Figure 5B shows that this mutant of P/CAF acetylation, we would expect the levels of
endogenous acetylated E2F1 to rise following P/CAFis able to stimulate transcription in co-operation with
DP1. However, the activity of this mutant E2F1-R–DP1 transfection. To establish if this is the case, the anti-
acetylated lysine antibody was used to immunoprecipitateheterodimer is refractile to P/CAF stimulation. Taken
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Fig. 4. DNA-binding activity of E2F1 is augmented by acetylation. (A) Acetylation of E2F1-DBD increases its DNA binding. The His-E2F1-DBD
(amino acids 92–195) was bacterially expressed and puriﬁed. DNA binding of unmodiﬁed [in the presence of GST–P/CAF (amino acids 352–632),
but the absence of AcCoA (lanes 5–7)] versus in vitro acetylated E2F1-DBD [in the presence of GST–P/CAF and AcCoA (lanes 2–4)] was tested by
EMSA by incubation of increasing amounts of these proteins with 32P-labelled E2F-binding site (50 fmol per reaction). Reaction products were
resolved by electrophoresis and visualized by autoradiography. (B) E2F1–DP1 binds DNA more efﬁciently following acetylation of E2F1. His-E2F1
full-length protein was bacterially expressed, puriﬁed and in vitro acetylated [in the presence of P/CAF and AcCoA (lanes 7 and 8)] or not acetylated
[in the presence of either P/CAF, but not AcCoA (lanes 3 and 4) or P/CAF-ΔHAT and AcCoA (lanes 5 and 6)]. DNA binding was investigated by
incubation of these proteins with GST–DP1 and 32P-labelled E2F-binding site (50 fmol per reaction). Complexes were separated by electrophoresis
and autoradiographed. The DNA-binding ability of either E2F1 or DP1 alone is shown in lanes 1 and 2, respectively. (C) Increased DNA binding of
acetylated E2F1 is due to acetylation. The E2F1-R mutant, which contains lysines 117, 120 and 125 mutated to arginines, and which cannot be
acetylated (Figure 3C and D), was expressed in bacteria as a GST fusion protein, puriﬁed and tested for its DNA-binding ability after incubation
with either P/CAF (lanes 4–6) or P/CAF-ΔHAT (lanes 1–3) as described in (A) and (B).
Fig. 5. Acetylation of E2F1 stimulates its transcriptional activity. (A) U2OS cells were transfected with 0.5 μg of the CAT reporter gene plasmid and
1 μg of the indicated expression plasmid for E2F1 and DP1, 5 μg of pCX-P/CAF and P/CAF-ΔHAT, respectively, or equivalent empty vector.
Whole-cell extracts were used in CAT assays and the results were quantiﬁed on a PhosphoImager. The basal promoter activity of the CAT reporter
(TK promoter with 3 E2F sites) in the presence of empty expression vector was normalized to 1.0, and the activities of the remaining transfection
reactions were expressed relative to this, as fold activation of the basal promoter. The graph shows the average of three independent experiments.
(B) The effects of P/CAF on the transactivation potential of E2F1-R is shown, as assayed under the same conditions as described in (A).
endogenous E2F1, and Western blotting with anti-E2F caused by in vivo acetylation of endogenous E2F1 by
P/CAF.antibody was used to identify E2F1. In this experiment,
the amount of endogenous E2F1 protein was ﬁrst checked An increase in E2F1 protein levels by P/CAF can also
be detected on exogenously introduced E2F1 (Figure 6C,by Western blotting and equal amounts were used for the
immunoprecipitations. Figure 6B shows that the levels of lanes 1 and 2). The effect of P/CAF on transfected E2F1
is not as great as that seen on endogenous E2F1 in wholeacetylated E2F1 are elevated following P/CAF transfec-
tion, but not P/CAF ΔHAT transfection, suggesting that cells (Figure 6A). Nevertheless, the increase in E2F1
levels observed requires acetylation activity, since athe increase in E2F1 protein level is, at least partially,
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Fig. 6. Acetylation by P/CAF increases E2F1 protein level and prolonges its half-life. (A) 293T cells were either not transfected (lane 1) or
transfected with 5 μg of the indicated eukaryotic expression plasmids for P/CAF (lane 2), P/CAF-ΔHAT (lane 3), GCN5 (lane 4) and p300 (lane 5),
and 3 μg of RB (lane 6). At 24 h after the medium change, the cells were lysed in SDS-containing sample buffer and analysed by SDS–PAGE and
anti-E2F1 Western blot (C20) for endogenous E2F1 expression levels. (B) To investigate if the increase in E2F1 protein level is accompanied by
in vivo acetylation of endogenous E2F1, P/CAF- and P/CAF ΔHAT-transfected cells [as in (A)] were analysed by immunoprecipitation with anti-
acetylated lysine antibody (covalently coupled) and Western blot of the precipitates with anti-E2F (KH95) antibody. Equivalent amounts of E2F1
protein (of both transfection) were used for the immunoprecipitations. (C) 293T cells were transfected with E2F1 (lanes 1 and 2) or E2F1-R (lanes 3
and 4) in the presence (lanes 2 and 4) or absence (lanes 1 and 3) of P/CAF overexpression. SDS–PAGE and Western blot analysis with the anti-
E2F1 (C20) antibody revealed the effect of acetylation by P/CAF on the exogenous E2F1 protein level. (D) To determine the protein half-life of
E2F1 in the presence or absence of P/CAF, 293T cells were transfected with 2 μg of pcDNA3-E2F1 in the absence or presence of 8 μg of
pCX-P/CAF. At 24 h after the medium change, cells were pulse-labelled for 2 h with a [35S]methionine–cysteine mix. Chase was performed in
medium supplemented with 10-fold excess of cold methionine and cysteine for the time periods indicated. Cells were lysed and immuno-
precipitations were performed with the anti-E2F (C20) antibody. Immunoprecipitates were separated by SDS–PAGE, blotted and autoradio-
graphed. The intensity of the 35S-labelled proteins was measured densitometrically and calculated in comparison with the amount of E2F protein
present at time point zero, which was set at 100%. (E) The effects of P/CAF on the half-life of E2F1-R were assayed under the same conditions
as described in (D). Therefore, 6 μg of pcDNA3-E2F1-R were transfected with or without P/CAF into 293T cells.
P/CAF ΔHAT mutant cannot mediate this effect (data not levels detected with RB (Figure 6A, lane 6) has already
been demonstrated to result from an increase in E2F1shown). To show that E2F1 stability involves direct
acetylation of E2F1, we used the E2F1-R mutant. stability (Hateboer et al., 1996; Hofmann et al., 1996;
Campero and Flemington, 1997; Martelli and Livingston,Figure 6C (lanes 3 and 4) shows that this mutant is not
stabilized after P/CAF transfection. It is worth noting that 1999). Since P/CAF expression does not change the levels
of E2F1 RNA in the cell (data not shown), we exploredincreased stability of endogenous E2F1 is never observed
following transfection of exogenous E2F1, probably due the possibility that P/CAF acetylation of E2F1 affects its
half-life. The levels of exogenously expressed E2F1to the shut-off of endogenous E2F gene transcription
(Figure 6C). Collectively, these results indicate that protein (detected following immunoprecipitation) were
therefore monitored in a pulse–chase experiment, in eitheracetylation of E2F1 is necessary for the observed increase
in E2F1 protein levels. However, we cannot exclude the the presence or the absence of exogenous P/CAF.
Figure 6D shows that in the presence of P/CAF, E2F1 haspossibility that acetylation of other cellular components
by P/CAF may also contribute to this stabilizing effect. an increased half-life. In contrast, the stability of the
E2F1-R mutant, which cannot be acetylated by P/CAF, isWhat is noticeable in Figure 6C (lanes 3 and 4) is that
the E2F1-R mutant is expressed at lower levels than wild- not affected by P/CAF expression (Figure 6E). This result
suggests that acetylation of E2F1 is a necessary step fortype E2F1. The expression levels can be made equivalent
if the concentration of E2F1-R transfected is increased. the stabilizing effect of P/CAF.
However, what is also evident is that speciﬁc degradation
products are detectable when E2F1-R is transfected. This RB-associated HDAC deacetylates E2F1
Our results indicate that acetylation of E2F1 by P/CAFsuggested to us that lysines 117, 120 and 125 may be
involved in E2F1 stability and that acetylation by P/CAF leads to an increase in the transactivation potential of
E2F1. This would suggest that acetylation is relevant tomay be stabilizing the E2F1 protein. The increase in E2F1
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the ‘free’ state of E2F1, when it is not complexed with
the RB repressor protein. We and others have shown that
RB can repress the activity of E2F1, at least partly, by
tethering E2F1 to a histone deacetylase. We therefore
wanted to establish if the deacetylase associated with RB
can deacetylate E2F1. To ask this question, we puriﬁed
the RB-associated deacetylase present in nuclear extracts
using GST–RB. This endogenous deacetylase preparation
was then added to recombinant E2F1 that was acetylated
in vitro by P/CAF. Figure 7A shows that the acetylated
E2F1 protein can be deacetylated by the RB-bound
deacetylase.
We next sought to establish whether RB facilitates the
deacetylation of E2F1 by tethering the deacetylase to
E2F1. To this end, we generated recombinant baculovirus-
expressed HDAC1 deacetylase. Figure 7B shows that this
recombinant enzyme is capable of deacetylating P/CAF-
acetylated E2F1 (lane 1) and that this effect is stimulated
by RB (compare lanes 2 and 3). This stimulation was
greatly diminished when an RB pocket mutant (Δ22),
which cannot bind E2F, was used (lane 4). This suggests
that RB may facilitate deacetylation of E2F1, either
by stimulating the enzymatic capacity of HDAC or by
facilitating the interaction between HDAC1 and its sub-
strate E2F1. To distinguish between the two possibilities,
we used as a substrate for HDAC1 the DNA-binding
domain of E2F1, which cannot bind RB. Deacetylation of
this truncated E2F1 protein is inefﬁcient and is not
augmented by RB, supporting a tethering role for RB
(Figure 7C, lanes 1–4). Taken together, these results
indicate that the acetylation of E2F1 is likely to be relevant
to the non-RB-bound, ‘free’ form of E2F1, since tethering
of the deacetylase complex by RB can deacetylate E2F1.
Discussion
Here we show that E2F1 is an acetylated protein in vivo
and can be modiﬁed by acetylases in vitro. The enzyme
which most potently acetylates E2F1 is P/CAF. Other
acetylases (GCN5, p300 and CBP) can also acetylate
E2F1, though much less efﬁciently. It is still uncertain as
to which of these enzymes is responsible for the acetylation
of E2F1 in vivo but, given that P/CAF and p300/CBP can
be found in a complex, acetylation by either enzyme has Fig. 7. RB-associated HDAC deacetylates E2F1. (A) The RB-
associated deacetylase activity was puriﬁed from HeLa nuclear extractthe potential to regulate E2F1. Here we have pursued the
using GST–RB fusion protein bound to glutathione–Sepharose beads.consequences of acetylation by P/CAF.
As a control, only glutathione–Sepharose beads and GST protein wereThe residues acetylated by P/CAF lie adjacent to the
used. The recovered endogenous deacetylase complex was then added
DNA-binding domain of E2F1. An E2F1 mutant (E2F1-R) to 1 μg of recombinant acetylated His-E2F1 full-length fusion protein
[previously in vitro acetylated by GST–P/CAF (amino acids 352–632)that cannot be acetylated by P/CAF has been used to
in the presence of [3H]AcCoA]. The deacetylase assay was performedestablish how acetylation regulates E2F1 function. One
for 1 h at 37°C as described in Materials and methods. The histoneconsequence of acetylation is an increase in E2F1 DNA- deacetylase activity is given as d.p.m. of [3H]acetate released from thebinding potential. The acetylated residues do not take part full-length acetylated E2F1. (B) RB facilitates the deacetylation of
directly in DNA binding, as suggested by the recent crystal E2F1. Active HDAC1 deacetylase was expressed from baculovirus,
puriﬁed to homogeneity and assayed for its ability to deacetylate 1 μgstructure of the E2F4–DP1–DNA complex (Zheng et al.,
of in vitro acetylated His-E2F1 full-length protein (lane 2) alone or in1999). However, the close proximity of the acetylated
the presence of a saturating amount of either GST–RB fusion protein
residues to the N-terminal helical extension (a proposed (lane 3) or a GST–RB pocket mutant (GST–RBΔ22), which cannot
speciﬁcity helix) of the E2F1 DNA-binding domain makes bind E2F (lane 4). (C) RB tethers the deacetylase to E2F1. A 1 μg
aliquot of in vitro acetylated His-E2F1-DBD was subjected toit likely that a conformational change mediated by
deacetylation by puriﬁed recombinant, baculovirus-expressed HDAC1acetylation allows better access to DNA.
in the absence of RB (lane 2) or in the presence of a saturatingAcetylation by P/CAF leads to an increase in the
amount of either GST–RB recombinant protein (lane 3) or GST–RB
transcriptional activation capacity of E2F1.We can conﬁrm pocket mutant (GST–RBΔ22). The histone deacetylase activity is
that this ‘coactivation’ by P/CAF is due to its ability to given as d.p.m. of [3H]acetate released from the acetylated
His-E2F1-DBD.acetylate E2F1 since the E2F1-R mutant is unresponsive
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to P/CAF. However, we cannot conclude at this point of functional E2F1 may be dependent on the protection
from degradation mediated by proteins that associate withwhether the increase in transactivation is a direct con-
sequence of increased E2F1 DNA binding, or whether it. The stabilization of E2F1 by P/CAF acetylation may
be necessary to allow the accumulation of a non-RB-it is due to the increase in E2F1 stability caused by
acetylation. bound form of E2F1. When E2F1 is bound to RB, its
degradation is prevented, and the E2F–RB complex canAcetylation is likely to regulate E2F1 when it is in its
‘free’ state, dissociated from RB. In this state, E2F1 then act to repress transcription. However, when E2F1
has to function as an activator, in an RB-free state, acan act as a transcriptional activator, stimulating the
transcription of genes needed in S phase. Interestingly, protein distinct from RB has to mediate its stability. Such
a protein may well be a co-activator protein such asthe acetylated lysines are conserved only in the E2F family
members that have the potential to induce S phase, P/CAF, which, by deﬁnition, is likely to associate with
E2F1 when it is free from RB.suggesting that the acetylated form of E2F1 is relevant to
this function. Acetylation may promote the activator Thus, taken together, our data suggest the following
model. The E2F1 protein present as part of the E2F1–RBfunctions of E2F1 by increasing its ability to recognize
certain promoters. These promoters are likely to be those complex is likely to be unacetylated. This complex has
speciﬁc DNA-binding properties, is repressive for tran-whose activity is stimulated by E2F1 since the RB
repressor brings in a deacetylase complex that can scription and is stable because RB prevents E2F1 degrada-
tion by the ubiquitination pathway. In contrast, free E2F1deacetylate E2F1. Thus the E2F1–RB–HDAC repressor
complex is unlikely to have its DNA-binding potential is, at least partly, acetylated, has DNA-binding properties
distinct from the RB-bound complex, is able to activateregulated by acetylation of E2F1. We therefore predict
that the E2F–RB complex will contain unacetylated E2F1. transcription and is stable because co-activator proteins
such as P/CAF can prevent its degradation via anWe have not been able to verify this in vivo due to the
low afﬁnity of the anti-acetylated lysine antibody for acetylation-mediated pathway. What is still unclear is
whether these two complexes co-exist in the cell tempor-acetylated E2F1 (data not shown). The generation of
speciﬁc high afﬁnity antibodies recognizing acetylated ally, or whether the E2F–RB complex is replaced by an
E2F–P/CAF complex. From our current knowledge, theE2F1 is necessary to identify the complexes in which
acetylated E2F exists. expectation would be that the E2F1–RB complex is active
in G1, and the free E2F protein, complexed with P/CAF,What is still unclear is the necessity for an increase in
DNA-binding functions of free E2F1, relative to RB- is active in S phase. The generation of speciﬁc high
afﬁnity antibody reagents that recognize the acetylatedbound E2F1. One possibility is that acetylation not only
increases DNA binding, but also allows E2F1 to recognize form of endogenous E2F1 will be useful in addressing
this issue. What our results demonstrate is that acetylationa subset of promoters distinct from those normally bound
and repressed by E2F1–RB. Binding site selection experi- represents a novel mechanism by which the activity of
E2F1 is regulated.ments show that E2F1–RB may recognize a different
consensus site from that recognized by free E2F1 (Tao
et al., 1997). Also, there is evidence that certain E2F1
Materials and methodspromoter elements act positively whereas others act nega-
tively to regulate transcription (reviewed by Dyson, 1998). Cell culture, transfections and reporter gene assay
This difference may be, in part, a reﬂection of the different U2OS and 293T cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) with 10% fetal calf serum (FCS) and grown at 37°Cbinding speciﬁcity and afﬁnity of ‘free’ versus RB-bound
and 5% CO2. Cells were transfected by the calcium phosphate co-E2F1. The close proximity of the acetylated lysines to the
precipitation method (Hagemeier et al., 1993) for 14–18 h and then theE2F1 DNA-binding domain speciﬁcity helix is suggestive
medium was changed. After a 24–36 h incubation, the cells were washed
of a role for site selection. Crystallization of full-length in phosphate-buffered saline (PBS) and harvested.
E2F1 bound to DNA will establish if these lysines are an For E2F1–P/CAF interaction, U2OS cells (14 cm dishes) were
transfected with 8 μg of pCX-P/CAF. For immunoprecipitation ofintegral part of the speciﬁcity helix.
exogenous acetylated E2F1, 293T cells (14 cm dishes) were transfectedAnother consequence of acetylation uncovered by this
with 8 μg of either pCX-P/CAF or pCX-P/CAFΔHAT in the presence
analysis is an increase in the half-life of the E2F1 protein. or absence of either 3 μg of pcDNA3-E2F1 or 6 μg of pcDNA3-E2F1-R.
This is clearly demonstrated by the comparison of E2F1 For the reporter gene assay, U2OS cells (6 cm dishes) were transfected
with 1 μg of pcDNA3-E2F1 or 0.5 μg of pcDNA3-E2F1-R, 1 μg ofand the E2F1-R mutant. First, the E2F1-R protein accumu-
pCMV-DP1, 5 μg of pCX-P/CAF or pCX-P/CAF-ΔHAT, equivalentlates to much lower levels than wild-type E2F1. This is
amounts of empty vector and 0.5 μg of CAT reporter gene plasmid.
not due to a general misfolding of the protein because CAT assays were performed as described previously (Hagemeier et al.,
E2F1-R can bind DNA in vitro and activate transcription 1993). For the stability assay (by Western blot), 293T cells (6 cm dishes)
in vivo as efﬁciently as wild-type E2F1 (Figures 4 and were transfected with 5 μg of either pCX-P/CAF, pCX-P/CAFΔHAT,
pCMV-sport2 mGCN5 FU or pCMVβ-p300, or with 3 μg of pCMV-RB.5). Secondly, P/CAF overexpression stabilizes the E2F1
After transfection, the cells were resuspended in 100 μl of SDS-protein, but has no effect on the stability of the E2F1-R
containing sample buffer (Bannister and Kouzarides, 1996). For pulse–
mutant (Figure 6). The mechanism by which acetylation chase experiments, 293T cells (one 80 cm2 ﬂask per time point) were
protects from degradation is unknown. One possibility is transfected with 2 μg of pcDNA3-E2F1 or 6 μg of pcDNA3-E2F1-R,
8 μg of pCX-P/CAF and 1 μg of pCMV-luciferase. The transfectionthat acetylation protects E2F1 from a ubiquitin-mediated
efﬁciency of the pulse–chase extracts was determined by a luciferasedegradation. Such a mechanism has been proposed for the
assay from Promega according to the supplier’s instructions.
stabilizing effect of RB. An alternative, but not mutually
exclusive possibility is that acetylation protects E2F1 from Plasmid and recombinant proteins
a proteolytic cleavage. Mutations in the E2F1 cDNA (pGEX-E2F1 amino acids 89–437, a gift
from Dr Kaelin) were introduced using the Quick change mutagenesisThe E2F1 protein is inherently unstable, so accumulation
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kit (Stratagene) following the manufacturer’s instructions and veriﬁed Pulse–chase experiment
Pulse–chase experiments were performed as previously describedby DNA sequencing. Various domains of E2F1 and P/CAF were cloned
into the pGEX-2TK vector (Pharmacia). The E2F1 full-length cDNA (Hofmann et al., 1996) with some modiﬁcations. After transfection,
293T cells were starved for 1 h in methionine/cysteine-free medium andwas cloned from pCMV-NeoBam-E2F1 (a gift from Dr Kaelin) as
a BamHI–EcoRV fragment into BamHI–SmaI-digested pQE30 vector then labelled with 0.2 mCi of [35S]methionine/cysteine (NEN) per ﬂask
for 2 h. Cells were harvested (for time point zero) or incubated in the(Qiagen). P/CAF-ΔHAT (amino acids 352–658; Reid et al., 1998), CBP
(amino acids 1098–1877), RB, RBΔ22 and DP1 (amino acids 59–410) presence of a 10-fold excess of non-radioactive methionine and cysteine
for 1, 3 and 5 h and harvested thereafter. Equal amounts of radioactivewere expressed as GST fusion proteins, whereas GCN5 (amino acids 1–
427, a gift from Dr Berger) and p300 (amino acids 1071–1715) were lysate were used for immunoprecipitation of E2F1 by adjusting differ-
ences in the transfection efﬁciency with the aid of the luciferaseexpressed as His fusion proteins. The different GST and His fusion
proteins were expressed in Escherichia coli strain XA90 or M15 and assay. Immunoprecipitates were separated by SDS–PAGE, blotted and
autoradiographed. The intensity of 35S-labelled E2F protein waspuriﬁed as previously described (Brehm et al., 1998). The His-E2F1-
DNA-binding domain (DBD) was a gift of Steve Gamblin. calculated.
cDNAs of E2F1 and E2F1-R were introduced into BamHI–EcoRI and
BamHI–EcoRV sites, respectively, of the pcDNA3 vector (Invitrogen).
pCX-P/CAF vector was a gift from Dr Nakatani. pCX-P/CAF-ΔHAT, Acknowledgements
which contains a deletion of amino acids 497–526, was cloned by
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In vitro translations and pull-down assays
In vitro translations and GST pull-downs were performed essentially as
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